Plus Therapeutics Regains Nasdaq Compliance, Resolving Delisting Risk
Summary
Plus Therapeutics, Inc. announced it has regained compliance with Nasdaq's minimum bid price requirement, effectively resolving a prior delisting risk following a recent reverse stock split.
Key Events
-
Nasdaq Compliance Regained
Plus Therapeutics, Inc. received written notice from The Nasdaq Stock Market LLC confirming it has regained compliance with the minimum bid price requirement (Nasdaq Listing Rule 5550(a)(2)).
-
Delisting Risk Resolved
This notification resolves the previously disclosed Nasdaq delisting risk, which was a significant concern for the company's continued listing.
-
Follows Reverse Stock Split
Compliance was achieved after a one-for-twenty-five reverse stock split, which became effective on April 2, 2026.
Analysis
This filing is highly important as it confirms Plus Therapeutics has successfully resolved the Nasdaq minimum bid price deficiency, a significant risk previously highlighted in the company's 10-K. Regaining compliance removes a major overhang and potential delisting threat, which is crucial for maintaining investor confidence and market liquidity. While the compliance was achieved through a reverse stock split, the successful outcome of retaining the Nasdaq listing is a positive development for the company's operational stability and access to capital markets.
At the time of this filing, PSTV was trading at $7.56 on NASDAQ in the Industrial Applications And Services sector, with a market capitalization of approximately $50.1M. The 52-week trading range was $2.90 to $30.50. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.